| List of Illustrations | |
| Preface | |
| Acknowledgments | |
| Introduction: Exploring the Boundary between Politics and Science | |
| Social Interests in Promoting and Controlling Science and Technology | |
| Expansion of Government Support for Science, 1945 to the Late 1960s: The United States | |
| Expansion of Government Support for Science, 1945 to the Late 1960s: The United Kingdom | |
| Reassessing Science and Technology, 1965-1975 | |
| Deregulation and Selective Growth: 1970s and 1980s | |
| The Shaping of American and British Science Policy | |
| The Social Transformation of Recombinant DNA Technology, 1972-1982 | |
| Anticipations of Genetic Engineering, 1952-1970 | |
| The First Gene-Splicing Experiments, 1969-1973 | |
| Visions of a Commercial Future, 1974-1976 | |
| Genetic Engineering Enters the Business Arena, 1976-1979 | |
| The "Cloning Gold Rush," 1979-1982 | |
| A New Commercial Ethos | |
| A Transformation of Interest | |
| The Emergence and Definition of the Genetic Engineering Issue, 1972-1975 | |
| Social Interests in Genetic Engineering | |
| Precedents | |
| Emergence of the Recombinant DNA Issue, 1973-1974 | |
| Initiating Recombinant DNA Policy in the United States and the United Kingdom, 1972-1976 | |
| The Asilomar Conference, 24-27 February 1975 | |
| The Asilomar Legacy | |
| Initiating Government Controls in the United States and the United Kingdom, 1975-1976 | |
| The Politics of the NIH Guidelines | |
| Forming the NIH Recombinant DNA Advisory Committee | |
| Developing the NIH Guidelines, 1975-1976 | |
| The Hearing before the Director's Advisory Committee, February 1976 | |
| Promulgating the 1976 NIH Guidelines: Industry and the Public Enter the Policy Debate | |
| The Politics of Genetic Engineering in the United Kingdom | |
| The Williams Committee and the Formation of British Policy | |
| Forming the Genetic Manipulation Advisory Group | |
| The American and British Policy Paradigms: Variations on the Asilomar Legacy | |
| Defusing the Controversy: The Politics of Risk Assessment | |
| The Spread of the Recombinant DNA Controversy | |
| The Hazard Problem: A Case Study in the Closure of a Technical Controversy | |
| The Meetings at Bethesda, Falmouth, and Ascot | |
| Further Sources of "New Evidence" | |
| The Politics of Risk Assessment | |
| Dissemination/Legitimation | |
| Derailing Legislation, 1977-1978 | |
| The Politics of Government Control of Recombinant DNA Technology | |
| Biomedical Research as an "Affected Industry" | |
| The Rise and Fall of Recombinant DNA Legislation | |
| The Political Impact of the Legislative Defeat | |
| Revising the National Institutes of Health Controls, 1977-1978 | |
| The Social and Political Setting | |
| Revisions Proposed, 1977 | |
| The Director's Advisory Committee Meeting, December 1977 | |
| The Position of Private Industry, December 1977 | |
| Cloning Viral DNA: The Original Problem Reassessed | |
| Making the Changes: Initiating a Policy Reversal | |
| Revisions Released, December 1978 | |
| Operating the Genetic Manipulation Advisory Group, 1977-1978 | |
| The Social and Political Setting | |
| The Politics of GMAG | |
| Implementing the Williams Proposals, 1977 | |
| Developing the Brenner Scheme, 1977-1978 | |
| Dismantling the National Institutes of Health Controls: From Prevention to Crisis Intervention, 1979 | |
| The Social and Political Setting | |
| Industry, Academe, and the Politics of the NIH Controls | |
| The Status of the Hazards Debate | |
| The Wye Meeting | |
| The New Recombinant DNA Advisory Committee | |
| The Rowe-Campbell Proposal: The First Move toward Dismantling the NIH Controls | |
| A Turn in Discourse and Policy | |
| Dismantling the National Institutes of Health Controls but Preserving Quasi-regulation, 1980 | |
| Table of Contents provided by Publisher. All Rights Reserved. |